This inventor holds 3 USPTO granted patents and 2 EPO patents. Top assignee: Ucl Business Plc. Active years: 2020-2022.
Company Filing History:
Years Active: 2020-2022
Title: Neil Chaplin: Innovator in Bi-specific T-cell Engagers
Introduction
Neil Chaplin is a prominent inventor based in London, GB. He has made significant contributions to the field of bi-specific T-cell engagers, with a total of 3 patents to his name. His work focuses on innovative solutions for treating plasma-cell mediated diseases, such as multiple myeloma.
Latest Patents
One of Neil Chaplin's latest patents is a bi-specific T-cell engager specific for B cell maturation antigen (BCMA). This invention provides a bi-specific molecule that includes a first domain binding to BCMA and a second domain capable of activating a T cell. This molecule has potential applications in treating diseases like multiple myeloma. Another notable patent involves variants of the proliferation-inducing ligand (APRIL), which exhibit higher binding affinity to BCMA compared to wild-type APRIL. These variants also demonstrate altered binding kinetics and a higher BCMA:TACI binding ratio, achieved through specific mutations.
Career Highlights
Neil Chaplin is associated with UCL Business Plc, where he continues to develop innovative solutions in the field of immunotherapy. His work has garnered attention for its potential impact on treating serious medical conditions.
Collaborations
Neil collaborates with esteemed colleagues, including Martin Pulé and Kwee L Yong, who contribute to his research and development efforts.
Conclusion
Neil Chaplin is a dedicated inventor whose work in bi-specific T-cell engagers is paving the way for advancements in the treatment of plasma-cell mediated diseases. His innovative patents reflect his commitment to improving patient outcomes through scientific research.